Italy's CBD Twist: A Step Back Amidst Booming Global Green Gold?
Italy's CBD Twist: A Step Back Amidst Booming Global Green Gold?
The Italian government has controversially reclassified cannabidiol (CBD) as a narcotic. This latest development is another twist in the ongoing regulatory saga around the hemp-derived compound in the European country.
這個 意大利政府 有爭議地將大麻二酚（CBD）重新歸類爲 麻醉品。這一最新進展是歐洲國家圍繞大麻衍生化合物的持續監管傳奇的又一轉折。
Despite the global CBD market forecasting a growth from 4.9 Billion in 2022 to 47.22 billion by 2030, Italy seems to be taking a step back. The current anticipated CAGR for the industry stands at 21.2%.
儘管全球CBD市場預測到2030年將從2022年的49億個增長到472.2億美元，但意大利似乎正在退後一步。該行業目前預期的複合年增長率爲21.2％。
See Also: Italy Sparks Controversy by Reclassifying Oral CBD as a Narcotic: Uncertainty and Debate in the European Market
另請參閱： 意大利將口服CBD重新歸類爲麻醉品，引發爭議：歐洲市場的不確定性和爭論
Background
背景
Historically, the regulatory position in Italy has been inconsistent.
從歷史上看，意大利的監管狀況一直前後矛盾。
In 2020, a decree was issued tagging CBD as a narcotic, only to be repealed shortly after. A subsequent 2021 decree met the same fate, with the regional court of Lazio advising alignment with EU regulations.
2020年，發佈了一項法令，將CBD標記爲麻醉品，但不久之後才被廢除。隨後的2021年法令遇到了同樣的命運，拉齊奧地區法院建議與歐盟法規保持一致。
It's notable that in 2020, the European Commission, applicable to all EU member states, ruled that CBD shouldn't be classified as a narcotic. However, the Italian Ministry of Health has chosen to diverge from this stance. Their latest announcement, published in the Official Gazette, becomes effective from September 21, 2023.
值得注意的是，2020年，適用於所有歐盟成員國的歐盟委員會裁定，不應將CBD歸類爲麻醉品。但是，意大利衛生部選擇偏離這一立場。他們的最新公告發布在《官方公報》上，生效日期爲 2023年9月21日。
According to Hemp Today, key industry stakeholders, including Canapa Sativa Italia and Federcanapa, are publicly opposing this move, warning of its potential negative impact on businesses and the local CBD market. Expert neuropharmacologist, Viola Brugnatelli, underscored the economic repercussions, while legal expert Carlo Alberto Zaina urged industry unity against this decree.
據《今日大麻》報道，包括Canapa Sativa Italia和Federcanapa在內的主要行業利益相關者公開反對這一舉動，並警告其可能對企業和當地CBD市場產生負面影響。神經藥理專家維奧拉·布魯尼亞泰利強調了經濟影響，而法律專家卡洛·阿爾貝託·扎伊納則敦促行業團結起來反對該法令。
Despite these changes, Italy's medical cannabis market, which has witnessed steady growth over recent years, continues to source cannabis primarily from the Netherlands, Canada, Denmark, and Germany, with Aurora Cannabis Inc. (NASDAQ:ACB) among the top suppliers since 2019.
儘管發生了這些變化，但近年來穩步增長的意大利醫用大麻市場繼續主要從荷蘭、加拿大、丹麥和德國採購大麻， 奧羅拉大麻公司 納斯達克股票代碼：ACB）自2019年以來一直位居頂級供應商之列。
Cannabis Capital Conference In Chicago
芝加哥大麻資本會議
If you are interested in knowing more about the latest cannabis developments around the globe, consider joining us at the Benzinga Cannabis Capital Conference in Chicago this September 27-28.
如果您有興趣進一步了解最新的大麻發展 在全球各地，可以考慮加入我們 本辛加大麻資本會議 在 今年 9 月 27 日至 28 日的芝加哥。
Get your tickets today before prices go up and secure a spot at the epicenter of cannabis investment, retail, culture, and branding. All information is available on bzcannabis.com
在價格上漲之前立即購買門票，在大麻投資、零售、文化和品牌的中心佔有一席之地。 所有信息都可在 bzcannabis.com 上找到
Read Next: Italians To Enjoy Medical Marijuana Offerings From One Of The Biggest Cannabis Companies In The World
繼續閱讀： 意大利人將享受世界上最大的大麻公司之一提供的醫用大麻產品
Image by El Planteo
圖片由 El Planteo
譯文內容由第三人軟體翻譯。